For Immediate Release - ASCO 2022 Abstract #9004
Contact:
Frank DeSanto, Communications Manager, SWOG Cancer Research Network,...
Ryan Hohman, JD, Managing Director, Friends of Cancer Research/ Chair, Lung-MAP Public Affairs Committee: 202.944.6708 or rhohman@focr.org
Frank DeSanto, Communications and Public Relations Manager, SWOG, Lung-MAP Public Affairs Committee: 210.718.2941 or communications@swog.org
For Immediate Release - ASCO 2022 Abstract #9004
Contact:
Frank DeSanto, Communications Manager, SWOG Cancer Research Network,...
For Immediate Release
Contact:
Wendy Lawton, Communications Manager, SWOG Cancer Research Network, lawtonw@ohsu.edu, 503-348-8675...
The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI),...
Lung-MAP, the most collaborative and comprehensive lung cancer clinical trial active in the U.S., uses a targeted screening approach to match...
On March 4, 2015, the U.S. Food and Drug Administration (FDA) announced that it had approved Opdivo (nivolumab) for the treatment of patients with...
Trial will Close One of Five Trial Sub-Studies: Other four sub-studies of targeted treatments for squamous cell lung cancer will continue to...
Groundbreaking study in squamous cell lung cancer opens at more than a hundred and fifty new locations
Lung-MAP is a multi-drug, multi-arm, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer.
© Copyright 2023 Lung Cancer Master Protocol (Lung-MAP) Clinical Trials, All rights reserved